A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis

Molecular Pharmacology

Volumn 72, Issue 2, 2007, Pages 477-484

  Benneyworth, Michael A ^a   Xiang, Zixiu ^a   Smith, Randy L ^a   Garcia, Efrain E ^a   Conn, P Jeffrey ^a   Sanders Bush, Elaine ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; BIPHENYLINDANONE A; GLUTAMIC ACID; INDANONE DERIVATIVE; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; PROTEIN FOS; PSYCHEDELIC AGENT; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; EXCITATION; HEAD TWITCH; LIGAND BINDING; MALE; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; POSTSYNAPTIC POTENTIAL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ALLOSTERIC REGULATION; ANIMALS; BIPHENYL COMPOUNDS; EXCITATORY POSTSYNAPTIC POTENTIALS; HALLUCINOGENS; INDANS; MALE; MICE; MICE, INBRED ICR; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-FOS; PSYCHOTIC DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 34547198448     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.035170     Document Type: Article

References (40)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20:92-96.
2. Aghajanian GK and Marek GJ (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 36:589-599.
3. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825:161-171.
4. Aghajanian GK and Marek G (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31:302-312.
5. Cartmell J, Monn JA, and Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161-170.
6. Chaudhuri A (1997) Neural activity mapping with inducible transcription factors. Neuroreport 8:3-7.
7. Cleghorn JM, Garnett ES, Nahmias C, Firnau G, Brown GM, Kaplan R, Szechtman H, and Szechtman B (1989) Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res 28:119-133.
8. Ebmeier KP, Lawrie SM, Blackwood DH, Johnstone EC, and Goodwin GM (1995) Hypofrontality revisited: a high resolution single photon emission computed tomography study in schizophrenia. J Neurol Neurosurg Psychiatry 58:452-456.
9. Franklin KBJ and Paxinos G (2003) The Mouse Brain in Stereotaxic Coordinates, 2nd ed, Academic Press Inc., San Diego.
10. Galici R, Echemendia NG, Rodriguez AL, and Conn PJ (2005) A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 315:1181-1187.
11. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
12. Gewirtz JC and Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569-576.
13. Greco B, Invernizzi RW, and Carli M (2005) Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology (Berl) 179:68-76.
14. Gresch PJ, Strickland LV, and Sanders-Bush E (2002) Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors. Neuroscience 114:707-713.
15. Hermle L, Funfgeld M, Oepen G, Botsch H, Borchardt D, Gouzoulis E, Fehrenbach RA, and Spitzer M (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32:976-991.
16. Hughes P and Dragunow M (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 47:133-178.
17. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, and Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem 46:3189-3192.
18. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, and Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179:271-283.
19. Kaplan RD, Szechtman H, Franco S, Szechtman B, Nahmias C, Garnett ES, List S, and Cleghorn JM (1993) Three clinical syndromes of schizophrenia in untreated subjects: relation to brain glucose activity measured by positron emission tomography (PET). Schizophr Res 11:47-54.
20. Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, and Schoepp DD (1998) LY341495 is a nanamolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 1:1-12.
21. Klodzinska A, Bijak M, Tokarski K, and Pilc A (2002) Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73:327-332.
22. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, et al. (2004) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179:303-309.
23. 2/1C receptor activation causes a localized expression of the immediate-early gene c-fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience 53:457-463.
24. Marek GJ, Wright RA, Gewirtz JC, and Schoepp DD (2001) A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 105:379-392.
25. Marek GJ, Wright RA, Schoepp DD, Monn JA, and Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87.
26. Moghaddam B and Adams B (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.
27. Ohishi H, Shigemoto R, Nakanishi S, and Mizuno N (1993a) Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 53:1009-1018.
28. Ohishi H, Shigemoto R, Nakanishi S, and Mizuno N (1993b) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J Comp Neurol 335:252-266.
29. Platenik J, Kuramoto N, and Yoneda Y (2000) Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci 67:335-364.
30. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
31. Schoepp DD (2006) New directions in the treatment of schizophrenia: Modulators of mGlu2 and/or mGlu3 receptors. Neuropsychopharmacology 31:S25.
32. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, and Millan MJ (1995) (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273:101-112.
33. 2A heteroreceptors on thalamocortical glutamatergic neurons. J Neurosci 20:8846-8852.
34. Vollenweider FX and Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56:495-507.
35. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, and Angst J (1997a) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9-24.
36. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, and Angst J (1997b) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372.
37. Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Babler A, Vogel H, and Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902.
38. Willins DL and Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706.
39. Winter JC, Eckler JR, and Rabin RA (2004) Serotonergic/glutamatergic interactions: the effects of mGluR2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology (Berl) 172:233-240.
40. Zhai Y, Carolyn GA, Zhai J, Nisenbaum ES, Johnson MP, and Nisenbaum LK (2003) Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 28:45-52.